As the investment community enters its annual period of portfolio rebalancing and strategic repositioning for the coming year, a critical examination of underperforming assets becomes essential. While earlier analyses have highlighted the standout performers within the Dow Jones Industrial Average (DJI) and the S&P 500 Index (SPX) for 2025, the current narrative is dominated by a conspicuous underachiever: UnitedHealth Group Inc. (NYSE: UNH). This healthcare behemoth has decisively claimed the title of the worst performer on the Dow this year, its trajectory marred by a confluence of profound internal crisis and severe financial headwinds.
The company's downward spiral began in December 2024 with a catastrophic event: the murder of its CEO, Brian Thompson. This tragedy plunged UnitedHealth into a state of instability and controversy from which it has struggled to recover. The foundational shock was compounded in April by a significant earnings miss, coupled with a lowered full-year outlook directly attributed to higher-than-expected medical costs. This one-two punch violently ejected the stock from its previous perch above the $600 level. Subsequent rally attempts throughout the year proved feeble and unsustainable; each run lost decisive momentum around the $325 resistance mark. Most recently, the share price gapped down to depths not seen since April 2020, and as of the latest data, UNH trades at $324.13. The equity is currently pacing toward its seventh consecutive daily loss, poised to conclude 2025 with a dismal record of only five monthly gains. Year-to-date, the security has hemorrhaged more than 35% of its value.
Intriguingly, and perhaps counter-intuitively, this stark underperformance has not extinguished all bullish sentiment—at least among a specific cohort. Short-term options traders continue to lean bullish, a stance starkly illustrated by UnitedHealth's Schaeffer's put/call open interest ratio (SOIR). This ratio currently sits at a level higher than only 4% of all annual readings, indicating a historically extreme preference for calls over puts. This positioning suggests that a significant segment of the options market is either betting on a sharp rebound or has been repeatedly caught on the wrong side of the downtrend. Should this optimistic positioning begin to unwind—through the closure of call positions or the initiation of new puts—it could generate substantial additional selling pressure, creating fresh headwinds for the already beleaguered stock.
Further insight into market expectations can be derived from volatility metrics. UnitedHealth sports a Schaeffer's Volatility Index (SVI) of 30%, which resides in the low 19th percentile of its annual range. This indicates that near-term option premiums are priced for remarkably low volatility expectations. However, the stock's Schaeffer's Volatility Scorecard (SVS) tells a different story about its past behavior. With an SVS of 99 out of 100, UNH has consistently made larger price moves than options traders had anticipated over the past year, meaning it has a strong tendency to overperform volatility expectations, often to the downside in the current context.
Amid this financial and market turmoil, UnitedHealth's management is engaged in a concerted effort to address systemic issues and rebuild its reputation. The company has pledged a series of operational improvements following the first independent, external reviews of its business practices, initiatives spearheaded by new CEO Stephen Hemsley. Hemsley, who assumed the role in the turbulent spring, commissioned these audits as part of a broader attempt to mend the company's waning consumer trust, which has suffered amid rising public and regulatory backlash over care delays and claim denials.
The independent analyses, conducted by FTI Consulting and the Analysis Group and released recently, did not unearth a definitive "smoking gun" proving that UnitedHealth leveraged its market dominance to artificially inflate profits. Nevertheless, the reports did pinpoint serious, ongoing deficiencies in three critically scrutinized areas: the risk assessment and diagnostic coding processes within its massive Medicare Advantage operations; the care review and prior authorization protocols at its UnitedHealthcare insurance arm; and the transparency with which its pharmacy benefit manager, Optum Rx, passes drug manufacturer rebates and discounts along to clients.
From a technical analysis perspective, the chart reveals critical price levels that will dictate UNH's next major move. The immediate upside target, representing a potential area for a technical rebound or short-term profit-taking, is identified at the 0.382 Fibonacci retracement level of the recent down leg, calculated at $328.09. Conversely, the architecture beneath the current price is built on three primary support zones, which are likely to be tested if the selling pressure persists. These key defensive layers are situated at the psychological $300 level, a more substantial floor at $280, and a major long-term support zone near $240, which would represent a critical test of market confidence in the company's recovery narrative. The interaction between these technical levels, the unresolved fundamental challenges, and the crowded options market sentiment will define UnitedHealth's path as it seeks to reverse one of the most dramatic downturns in the blue-chip index.
The company's downward spiral began in December 2024 with a catastrophic event: the murder of its CEO, Brian Thompson. This tragedy plunged UnitedHealth into a state of instability and controversy from which it has struggled to recover. The foundational shock was compounded in April by a significant earnings miss, coupled with a lowered full-year outlook directly attributed to higher-than-expected medical costs. This one-two punch violently ejected the stock from its previous perch above the $600 level. Subsequent rally attempts throughout the year proved feeble and unsustainable; each run lost decisive momentum around the $325 resistance mark. Most recently, the share price gapped down to depths not seen since April 2020, and as of the latest data, UNH trades at $324.13. The equity is currently pacing toward its seventh consecutive daily loss, poised to conclude 2025 with a dismal record of only five monthly gains. Year-to-date, the security has hemorrhaged more than 35% of its value.
Intriguingly, and perhaps counter-intuitively, this stark underperformance has not extinguished all bullish sentiment—at least among a specific cohort. Short-term options traders continue to lean bullish, a stance starkly illustrated by UnitedHealth's Schaeffer's put/call open interest ratio (SOIR). This ratio currently sits at a level higher than only 4% of all annual readings, indicating a historically extreme preference for calls over puts. This positioning suggests that a significant segment of the options market is either betting on a sharp rebound or has been repeatedly caught on the wrong side of the downtrend. Should this optimistic positioning begin to unwind—through the closure of call positions or the initiation of new puts—it could generate substantial additional selling pressure, creating fresh headwinds for the already beleaguered stock.
Further insight into market expectations can be derived from volatility metrics. UnitedHealth sports a Schaeffer's Volatility Index (SVI) of 30%, which resides in the low 19th percentile of its annual range. This indicates that near-term option premiums are priced for remarkably low volatility expectations. However, the stock's Schaeffer's Volatility Scorecard (SVS) tells a different story about its past behavior. With an SVS of 99 out of 100, UNH has consistently made larger price moves than options traders had anticipated over the past year, meaning it has a strong tendency to overperform volatility expectations, often to the downside in the current context.
Amid this financial and market turmoil, UnitedHealth's management is engaged in a concerted effort to address systemic issues and rebuild its reputation. The company has pledged a series of operational improvements following the first independent, external reviews of its business practices, initiatives spearheaded by new CEO Stephen Hemsley. Hemsley, who assumed the role in the turbulent spring, commissioned these audits as part of a broader attempt to mend the company's waning consumer trust, which has suffered amid rising public and regulatory backlash over care delays and claim denials.
The independent analyses, conducted by FTI Consulting and the Analysis Group and released recently, did not unearth a definitive "smoking gun" proving that UnitedHealth leveraged its market dominance to artificially inflate profits. Nevertheless, the reports did pinpoint serious, ongoing deficiencies in three critically scrutinized areas: the risk assessment and diagnostic coding processes within its massive Medicare Advantage operations; the care review and prior authorization protocols at its UnitedHealthcare insurance arm; and the transparency with which its pharmacy benefit manager, Optum Rx, passes drug manufacturer rebates and discounts along to clients.
From a technical analysis perspective, the chart reveals critical price levels that will dictate UNH's next major move. The immediate upside target, representing a potential area for a technical rebound or short-term profit-taking, is identified at the 0.382 Fibonacci retracement level of the recent down leg, calculated at $328.09. Conversely, the architecture beneath the current price is built on three primary support zones, which are likely to be tested if the selling pressure persists. These key defensive layers are situated at the psychological $300 level, a more substantial floor at $280, and a major long-term support zone near $240, which would represent a critical test of market confidence in the company's recovery narrative. The interaction between these technical levels, the unresolved fundamental challenges, and the crowded options market sentiment will define UnitedHealth's path as it seeks to reverse one of the most dramatic downturns in the blue-chip index.
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.